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Abstract
Objective: To evaluate the performance of Finnish Diabetes Risk Score (FINDRISC) in detecting undiagnosed diabetes and
prediabetes among U.S. adults by gender and race.
Methods: This cross-sectional analysis included participants (aged $20 years) from the National Health and Nutrition
Examination Survey (NHANES) 1999–2010. Sensitivity, specificity, area under the receiver operating characteristic (ROC)
curve and the optimal cutoff points for identifying undiagnosed diabetes and prediabetes were calculated for FINDRISC by
gender and race/ethnicity.
Results: Among the 20,633 adults ($20 years), 49.8% were women and 53.0% were non-Hispanic White. The prevalence of
undiagnosed diabetes and prediabetes was 4.1% and 35.6%, respectively. FINDRISC was positively associated with the
prevalence of diabetes (OR= 1.48 for 1 unit increase, p,0.001) and prediabetes (OR= 1.15 for 1 unit increase, p,0.001). The
area under ROC for detecting undiagnosed diabetes was 0.75 for total population, 0.74 for men and 0.78 for women
(p = 0.04); 0.76 for White, 0.76 for Black and 0.72 for Hispanics (p = 0.03 for White vs. Hispanics). The area under ROC for
detecting prediabetes was 0.67 for total population, 0.66 for men and 0.70 for women (p,0.001); 0.68 for White, 0.67 for
Black and 0.65 for Hispanics (p,0.001 for White vs. Hispanics). The optimal cutoff point was 10 (sensitivity = 0.75) for men
and 12 (sensitivity = 0.72) for women for detecting undiagnosed diabetes; 9 (sensitivity = 0.61) for men and 10
(sensitivity = 0.69) for women for detecting prediabetes.
Conclusions: FINDRISC is a simple and non-invasive screening tool to identify individuals at high risk for diabetes in the U.S.
adults.
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Introduction
Type 2 diabetes prevalence in the U.S. is increasing dramat-
ically, with the age-adjusted prevalence of adults (aged 18 years or
older) increased from 4.5% in 1995 to 8.2% in 2010 [1]. The
economic cost of diabetes in the U.S., estimated by American
Diabetes Association (ADA), was $255 billion in 2012, a 41%
increase since 2007 [2]. Under the current diabetes incidence
trend, it is projected that 1 in every 3 U.S. adults will have diabetes
(diagnosed or undiagnosed diabetes) in 2050 [3]. Additionally, a
relative high rate of undiagnosed diabetes has been identified in
the U.S., accounting for about 27% of the total diabetes cases of all
ages [1]. Also, in 2005–2008, 35% of U.S. adults (older than 20
years) and 50% of those older than 65 years had prediabetes, a
high risk stage of type 2 diabetes [4].
Emerging evidence from both observational studies and
randomized controlled trials (RCTs) has clearly shown that people
with high risk for type 2 diabetes or people at prediabetes stage will
be benefited by early identification followed by the intensive
lifestyle intervention and pharmacological treatment [5–9]. Thus,
identifying those individuals becomes crucial and cost efficient.
The traditional diabetes screening methods, including the fasting
plasma glucose (FPG), the 2-hour oral glucose tolerance test
(OGTT) or HbA1c test, are invasive, inconvenient and expensive
[10,11]. This is also one of the important reasons why there are a
large number of diabetic patients remaining undiagnosed. Seeking
a simple, reliable and cost-effective diabetes screening method,
such as a diabetes risk score that can be easily conducted in clinical
or community setting, has been proposed by many investigators in
many countries [12–23]. However, a recent research indicated
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that diabetes risk scores derived from certain populations could
have low validity when they were applied to the other populations
[24]. Therefore, it is important to evaluate the performance of the
diabetes risk score in a specific population before applying it in this
population [24].
World-wide, more than 10 diabetes risk assessment tools have
been developed from different populations [12–23]. Among them,
Finnish Diabetes Risk Score (FINDRISC) is the most commonly
used risk score in detecting undiagnosed diabetes. FINDRISC has
multiple advantages over other diabetes risk scores. First,
FINDRISC is a simple self-administered questionnaire which
can be used as an initial diabetes screening in primary care or
community settings. It can be well understood and easily
calculated by the lay person or clinical personnel without any
laboratory test. Second, FINDRISC was developed in a prospec-
tive study with an excellent performance in predicting the 10-year
incident diabetes in Finnish population [16]. Third, FINDRISC
includes 8 clearly defined questions that cover all well known risk
factors of diabetes. Last but not the least, FINDRISC has been
evaluated in detecting individuals with undiagnosed diabetes and
prediabetes in a cross-sectional study in Finland [25] and 15 other
countries or regions and gained good validity in most of these
populations [24,26–39]. However, most previous studies have
been conducted in European countries with the majority of
participants as Caucasians [26–32] or other single racial groups
[24,33–39]. The performance of the FINDRISC in the U.S., a
country with multiple racial/ethnic groups, is still unknown. The
aim of this study is to evaluate the performance of FINDRISC in
identifying undiagnosed diabetes and prediabetes in U.S. popu-
lation by sex and race/ethnicity. With the increase in the
prevalence of type 2 diabetes and its associated economic burden
in the U.S., identifying type 2 diabetes at early stage with simple
and accurate methods becomes a public health priority.
Methods
Study Population (NHANES 1999–2010)
The National Health and Nutrition Examination Survey
(NHANES) is designed to assess the health and nutritional status
of adults and children in the U.S. through surveys including
national representative sample of non-institutionalized U.S.
population. From 1999, the NHANES survey became a contin-
uous program and data were collected every 2 years. The
NHANES 2009–2010 is the most updated survey released for
public and research. Details of the NHANES design and
procedures are available at Center for Disease Control and
Prevention (CDC) website [40]. In brief, NHANES 1999–2010
includes 6 cross-sectional surveys (1999–2000, 2001–2002, 2003–
2004, 2005–2006, 2007–2008, 2009–2010) that were based on a
stratified multistage probability sampling design. Low-income
persons, adolescents aged 12–19 years, persons aged 60 years or
older, African Americans and Mexican Americans were over-
sampled in NHANES surveys. Each survey included two
components: a household interview and a health examination.
The household interview included questionnaires on demographic,
socioeconomic, dietary, and health-related information. The
health examination component consisted of medical, dental, and
physiological measurements, as well as laboratory tests adminis-
tered by trained medical personnel in a fully equipped mobile
examination center (MEC).
For this study, we included all participants from NHANES
1999–2010 aged 20 years or above who had complete information
to calculate FINDRISC. The final sample size included in this
analysis was 20,633.
Finnish Diabetes Risk Score
FINDRISC was originally developed to predict the 10 years
diabetes incidence in Finnish population (35 to 64 years) in a
cohort study [16]. The FINDRISC is calculated based on a simple
questionnaire with 8 questions, including age (years), body mass
index (BMI: kg/m2), waist circumference (WC: cm), history of
antihypertensive drug treatment, history of high blood glucose,
family history of diabetes, daily consumption of fruits, berries, or
vegetables (consume every day vs. not), and daily physical activity
(having at least 30 minutes of physical activity during work or at
leisure time vs. not) [16]. The questionnaire can be completed
without any laboratory test. The answer of every question is
assigned with different weighted scores according to the risk
increase associated with the respective values in the regression
model in the original cohort. The final score is the sum of the
scores from 8 questions and ranges from 0 to 26 [25].
In our study, BMI and WC were identified from the
anthropometric data measured by trained personnel in MEC.
Daily physical activity time was calculated as the sum of the
minutes spent on physical activity for commuting, recreation, and
work on average for each day. The frequency of vegetables, fruits
or berries consumption was initially collected through 24-hour
food recall, and only those who consumed vegetables or fruits at
least 100 grams/day were considered as consuming vegetables or
fruits or berries every day. The answers to all the other questions
of the FINDRISC were identified via self-reported answers from
NHANES questionnaires.
Diabetes and Prediabetes Definition and Measurement
In the present study, we categorized individuals into different
groups according to their self-reported diabetes status and
laboratory test results. The criteria of lab diagnosed diabetes and
prediabetes were based on the most updated ADA 2013 definitions
[41]. Specifically, self-reported/diagnosed diabetes was defined as
having answered ‘‘Yes’’ to the question ‘‘Other than during
pregnancy, have you ever been told by a doctor or health
professional that you have diabetes or sugar diabetes?’’. Undiag-
nosed diabetes was defined as having HbA1c $6.5%, or FPG $
126 mg/dl, or 2-h OGTT plasma glucose $ 200 mg/dl, but not
having self-reported diabetes. Diabetes included individuals either
in the self-reported/diagnosed diabetes category or in the
undiagnosed diabetes category. Prediabetes was defined as not
having diagnosed or undiagnosed diabetes, but having HbA1c
between 5.7 and 6.4%, or FPG between 100 and 125 mg/dl, or 2-
h OGTT plasma glucose between 140 and 199 mg/dl. Normal
glycemic level included individuals who did not have self-reported
diabetes and did not meet the diabetes and prediabetes diagnosis
criteria according to the FPG, 2-h OGTT, and/or HbA1c values.
Statistical Analysis
Primary Analyses. Descriptive data on study participants’
characteristics were expressed as means 6 standard deviations
(SD) for continuous variables and percentage for categorical
variables. Student’s t-test and x2 test were applied to compare
continuous and categorical variables, respectively. These proce-
dures allow users to specify primary sampling units, stratification
identification and sampling weights in the statistical procedures, as
well as to generate design-adjusted means, percentages, standard
errors (SE) and regression coefficients (b). Unadjusted and adjusted
logistic regressions were performed to estimate the association of
FINDRISC with diabetes, undiagnosed diabetes, and prediabetes,
separately, where the smoking status (never, former, vs. current
smoker), current alcohol drinking (yes vs. no), highest education
level (with vs. without college degree or above), annual household
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income (more than vs. less than annual household income of
$45,000) have been controlled in the adjusted analyses. Sensitivity,
specificity, positive (PV+) and negative (PV-) predictive values
were calculated for each FINDRISC score from 5 to 15 points for
detecting undiagnosed diabetes (individuals with self-reported
diabetes were excluded from this analysis) and prediabetes
(individuals with self-reported or undiagnosed diabetes were
excluded from this analysis). Gender- and race-specific receiver
operating characteristic (ROC) curves were constructed to visually
show the relationship between true-positive (sensitivity) and false
positive (1-specificity). The area under the curve (AUC) was used
to evaluate the performance of FINDRISC in detecting undiag-
nosed diabetes and prediabetes. An AUC=0.5 indicated the test
performed no better than chance and AUC=1.0 indicated perfect
discrimination. The optimal cutoff points were determined by the
point with the shortest distance in the ROC curve which was
calculated as the square root of [(1-sensitivity)2 + (1- specificity)2]
[42]. All the statistical analyses were performed using SAS
software, version 9.3 (SAS Institute, Cary, NC).
Secondary Analyses. Our secondary analyses were aimed to
1) compare FINDRISC with another diabetes risk score developed
among Americans [12]; 2) conduct a stratified analysis by age
(,65 vs. $65 years of age); and 3) conduct a sensitivity analysis
among a subgroup of individuals who had all results of FPG,
OGTT and HbA1c.
Results
A total of 20,633 adults aged $20 years (mean: 47.5617.8
years) were included in this analysis. Characteristics of participants
according to the FINDRISC group were presented in Table 1.
Around half of the population were women (49.79%), non-
Hispanic White (52.97%), having household income less than
$45,000/year (51.16%), currently married (56.42%) and having
college degree or above (51.51%). The majority of the population
were current alcohol drinkers (72.58%) but were non-smokers
(78.47%). Among all participants of NHANES 1999–2010, the
weighted percentage of self-reported/diagnosed diabetes, undiag-
nosed diabetes and prediabetes were 10.47%, 4.14% and 35.55%,
respectively. Age, female percentage, percentage of annual
household income below $45,000, percentage of married status,
BMI, waist circumference, FPG, HbA1c, and systolic blood
pressure increased with greater FINDRISC score (for each, P,
0.0001).
Figure 1 shows the prevalence of diabetes (both self-reported
and undiagnosed diabetes, N= 20,633) and prediabetes (self-
reported/diagnosed and undiagnosed diabetes excluded,
N= 18,113) by gender and race/ethnicity across the six FIN-
DRISC groups (0–3, 4–6, 7–10, 11–14, 15–19, and 20–26). The
FINDRISC was positively associated with the presence of diabetes
and prediabetes in all the gender and racial/ethnic groups: peaked
in the highest FINDRISC score group (20–26 points). The
prevalence of diabetes increased from 0.83% to 93.99% for men
and from 0.44% to 90.27% for women in the lowest FINDRISC
group (0–3 points) compared to the highest FINDRISC group
(20–26 points) (Figure 1A). The same increasing trend was
identified by racial/ethnic group. In the highest FINDRISC
group (20–26 points), the prevalence of diabetes was 89.63%
among non-Hispanic White, 92.95% among non-Hispanic Black
and 93.77% among Hispanics (Figure 1B). The prevalence of
undiagnosed diabetes (N= 18,879) was also found to be positively
associated with FINDRISC after excluding the diagnosed
diabetes, with 28.57% for men, 18.97% for women, 22.00% for
non-Hispanic White, 29.17% for non-Hispanic Black, 15.79% for
Hispanics in the highest FINDRISC group (20–26 points) (data
not shown). After excluding all diabetic patients, the prevalence of
prediabetes also peaked in the highest FINDRISC group (20–26
points): 88.00% for men, 59.57% for women, 64.10% for non-
Hispanic White, 82.35% for non-Hispanic Black, and 68.75% for
Hispanics (Figure 1 C and D). Despite of the same positive
association trend for the 3 diabetic categories with FINDRISC,
there were gender and racial/ethnic differences in terms of the
distribution of the prevalence. Men had higher prevalence of
diabetes, undiagnosed diabetes and prediabetes than women in all
the FINDRISC score groups. Hispanics had a higher prevalence
of diabetes while Non-Hispanic Black had a higher prevalence of
undiagnosed diabetes and prediabetes over the other racial/ethnic
groups.
Results from the logistic regressions also showed significant
associations of FINDRISC with all diabetes, undiagnosed diabetes
and prediabetes. One unit increase in FINDRISC was associated
with a 48.2% (95% CI: 46.0%, 50.5%) increased odds of having
diabetes, a 22.3% (95% CI: 20.0%, 24.7%) increased odds of
having undiagnosed diabetes and a 14.9% (95% CI: 14.0%,
15.8%) increased odds of having prediabetes after adjusting for the
smoking status, alcohol drinking, highest education level, and the
annual household income (data not shown). There was no
interaction between gender and FINDRISC score, indicating the
associations between FINDRISC and the prevalence of diabetes,
undiagnosed diabetes or prediabetes were similar comparing men
with women.
As shown in Table 2, the sensitivity of FINDRISC for
identifying undiagnosed diabetes and prediabetes decreased as
the specificity increased in both men and women. At the cutoff
value of 10 in men (sensitivity = 74.68%; specificity = 62.74%) and
12 in women (sensitivity = 72.17%; specificity = 68.60%), the
distance in ROC was the shortest for undiagnosed diabetes (0.45
in men and 0.42 in women). Accordingly, using the optimal cutoff
point of FINDRISC of 9 in men (sensitivity = 60.94%; specificity
= 62.43%) and 10 in women (sensitivity = 68.72%; specifici-
ty = 60.89%) resulted in the shortest distance in ROC for
prediabetes (0.54 in men and 0.50 in women). We also evaluated
the racial/ethnic specific optimal cutoff points for both undiag-
nosed diabetes and prediabetes (data not shown). We found that
the best cutoff point for undiagnosed diabetes was 11 for non-
Hispanic White (sensitivity = 74.93%), 12 for non-Hispanic Black
(sensitivity = 71.25%), and 11 for Hispanics (sensitivity = 65.98%).
The optimal cutoff point for prediabetes was 10 for each race/
ethnicity, but with the highest sensitivity for non-Hispanic Black
(62.42%) and the lowest sensitivity for Hispanics (55.88%). By
combining all men and women, the optimal cutoff point for
undiagnosed diabetes was 11 (sensitivity = 72.13%; specifici-
ty = 65.48%); for prediabetes, the optimal cutoff point was 10
(sensitivity = 59.34%; specificity = 65.43%) in this U.S. population
(data not shown).
The area under the ROC curve for identifying undiagnosed
diabetes were 0.74 in men and 0.78 in women (p,0.001); 0.76 for
White, 0.76 for Black and 0.72 for Hispanics (p = 0.03 for White
vs. Hispanics) (Figure 2 A and B). Whereas for identifying
prediabetes, the area under the ROC curve was 0.66 for men and
0.70 for women (p,0.001); 0.68 for White, 0.67 for Black and
0.65 for Hispanics (p,0.001 for White vs. Hispanics) (Figure 2 C
and D). After combining all the men and women participants, the
area under the ROC curve was 0.75 for identifying undiagnosed
diabetes and 0.67 for identifying prediabetes.
We performed stratified analysis by age (,65 vs. $65 years of
age, men and women combined) because the original FINDRISC
was developed in a population with age younger than 65 years
Evaluation of Finnish Diabetes Risk Score in U.S.
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(data not shown). For undiagnosed diabetes, the area under the
ROC curve was 0.75 for all individuals, 0.75 for participants
younger than 65 years (N= 17,072), and 0.65 for participants aged
65 years or above (N= 3,561). The sensitivity (cutoff point = 10)
was 75.27% for participants younger than 65 years and 87.04%
for participants aged 65 years or above. For prediabetes, the area
under the ROC curve was 0.67 for all individuals, 0.66 for
participants younger than 65 years, and 0.57 for participants aged
65 years or above. The sensitivity (cutoff point = 9) was 61.40%
for participants younger than 65 years and 82.98% for participants
aged 65 years or above.
Discussion
In this large, cross-sectional study of national representative
sample of free-living adults in the U.S., we found that the
FINDRISC had good performance in identifying undiagnosed
Table 1. Characteristics of the participants aged 20 years or above in NHANES 1999–2010, by FINDRISC group.*
Characteristics FINDRISC Group P All Participants
1st 2nd 3rd 4th 5th
FINDRISC value
Mean (SD) 3.33 (2.05) 8.91 (1.43) 12.86 (0.83) 16.87 (1.63) 22.49 (1.38) ,.0001 9.49 (5.37)
Median (range) 4 (0–6) 9 (7–11) 13 (12–14) 17 (15–20) 22 (21–26) 9 (0–26)
N 6,126 7,311 3,687 2,845 664 20,633
Age, year 36.98 (14.28) 47.49 (17.45) 51.85 (17.17) 60.62 (13.20) 63.90 (10.11) ,.0001 47.49 (17.81)
Female, % 42.87 51.18 54.62 53.99 53.46 ,.0001 49.79
Race/Ethnicity, %
Non-Hispanic White 54.05 55.41 51.59 48.86 41.57 ,.0001 52.97
Non-Hispanic Black 16.68 16.00 19.88 22.07 27.56 18.11
Hispanics 23.84 24.93 25.14 26.12 27.71 24.90
Other{ 5.44 3.65 3.39 2.95 3.16 4.02
Annual household income, %
Above $45,000/year 51.34 48.60 43.40 37.49 32.38 ,.0001 46.42
Below $45,000/year 46.21 48.90 54.19 60.49 64.44 51.16
Other` 2.45 2.50 2.40 2.02 3.17 2.42
Marriage status (married), % 49.98 59.37 58.68 58.90 60.06 ,.0001 56.42
Education (have college degree
or above), %
57.03 52.81 49.93 41.51 37.66 ,.0001 51.51
Current smoking (yes), % 27.39 20.76 19.27 16.03 12.20 ,.0001 21.53
Current alcohol intake (yes), % 78.55 74.14 68.17 65.03 58.58 ,.0001 72.58
BMI, kg/m2 23.68 (3.05) 28.76 (5.62) 31.47 (6.06) 32.47 (6.00) 33.65 (6.09) ,.0001 28.41 (6.18)
Waist circumference, cm 84.36 (8.95) 98.81 (13.16) 105.24 (13.41) 108.51 (13.10) 112.35 (13.00) ,.0001 97.44 (15.25)
FPG1, mg/dl 93.86 (14.40) 99.31 (21.41) 106.25 (30.00) 126.26 (51.97) 161.15 (69.65) ,.0001 104.75 (33.66)
HbA1c, % 5.20 (0.41) 5.41 (0.64) 5.65 (0.89) 6.30 (1.47) 7.33 (1.60) ,.0001 5.58 (0.97)
Systolic BP 115.81 (14.89) 122.77 (18.21) 126.46 (18.61) 132.65 (20.23) 133.39 (20.93) ,.0001 123.07 (18.70)
Diastolic BP 68.79 (11.55) 70.65 (13.10) 71.55 (13.59) 70.91 (14.81) 67.35 (15.20) ,.0001 70.19 (13.13)
Diabetes, %
unweighted 0.93 4.17 11.09 39.30 99.10 ,.0001 12.34
Weighted 1.05 4.54 11.01 39.33 98.27 10.47
Undiagnosed diabetes, %
Unweighted 0.85 3.31 6.54 9.00 0.30 ,.0001 3.84
Weighted 0.97 3.61 7.35 11.03 0.27 4.14
Prediabetes, %
Unweighted 16.59 28.70 36.94 33.74 0.60 ,.0001 26.37
Weighted 24.22 39.76 48.73 42.07 1.73 35.55
Data are means (SD) except where noted otherwise.
*FINDRISC group: = 1 if score,7, = 2 if score 7–11, = 3 if score 12–14, = 4 if score 15–20, = 5 if score .20;
{Other race, including multiracial;
`The participants select the annual household income as over $20,000;
1Fasting plasma glucose.
doi:10.1371/journal.pone.0097865.t001
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diabetes and prediabetes in both men and women in all racial/
ethnic groups.
Type 2 diabetes usually starts from increased insulin resistance,
a disorder that cells cannot respond to insulin normally and the
pancreas gradually loses its ability to generate enough insulin. Two
population-based studies have confirmed that the FINDRISC is
associated with insulin resistance [43,44], which supports the use
of FINDRISC in detecting type 2 diabetes from the biological
aspect.
The current ADA guideline for type 2 diabetes screening among
asymptomatic population is based on the laboratory testing [45].
However, there is always a trade-off between simplicity and
accuracy for each screening method. Thus, using a simple and
valid questionnaire as a preliminary screening method followed
with more invasive and accurate diagnosis in primary care and/or
community settings, can be a cost-effective and practical method.
FINDRISC is such a simple and non-invasive diabetes risk score
which can be well understood by lay people and easily calculated
by the lay people or clinical personnel without any laboratory test.
It has been evaluated and performed well in many European
countries [26–32]. To our knowledge, this study is the first study to
validate the FINDRISC in national representative population in
U.S.. As we expected, FINDRISC had a good validity in detecting
undiagnosed diabetes and prediabetes in the U.S. adults. The
areas under ROC curve for detecting undiagnosed diabetes were
0.74 in men and 0.78 in women in the U.S., which were very
similar with those in other European populations. FINDRISC can
also be used to detect prediabetes with the areas under ROC curve
of 0.66 for men and 0.70 for women.
A risk score for undiagnosed diabetes using the data of
NHANES 1999-2004 was developed by Bang et al. in 2009
[12]. This risk score (NHANES DRS) is calculated out of 6
variables, including age, sex, family history of diabetes, personal
history of hypertension, obesity, and physical activity. Although
NHANES DRS is comprised of readily available health informa-
tion without using any laboratory test results and is originated
among Americans, it was constructed from a crosssectional
dataset. The definition of diabetes used in developing this risk
score was only based on the fasting plasma glucose value, ignoring
the OGTT or HbA1c value. In addition, NHANES DRS does not
use any information on dietary intake which is well known to play
an important role in diabetes development. However, as the
NHANES DRS was developed from U.S. populations, it could be
informative to compare FINDRISC and NHANES DRS using the
current dataset. For undiagnosed diabetes, the area under the
ROC curve of NHANES DRS was 0.77 (vs. 0.75 of FINDRISC)
in all individuals, 0.76 (vs. 0.74 of FINDRISC) in men, and 0.78 in
women (vs. 0.78 of FINDRISC). Although NHANES DRS has the
advantage of being generated using NHANES data, the
FINDRISC has very similar discriminating ability as compared
to NHANES DRS from our results.
Compared with previous evaluation of FINDRISC in European
populations, the most difference of this study is the composition of
the study participants, the sample size and the diabetes diagnosis
criteria. For every previous evaluation in Europe, the study
population was all middle aged or old participants or patients with
one or more cardiovascular disease risk. However, the participants
of our study are nationally representative U.S. adults aged 20 years
or older, which indicates the FINDRISC performs well not only in
high risk population but also in the general free-living population.
Although our stratified analysis indicated that the discriminating
ability of FINDRISC is lower in people aged 65 years or above,
the sensitivity was 87.04% for undiagnosed diabetes and 82.98%
for prediabetes, which is acceptable for a first line screening tool.
Figure 1. Prevalence of diabetes (A and B) and prediabetes (C and D) by Finnish Diabetes Risk Score (FINDRISC) by gender and
race/ethnicity, in US men and women aged 20 years or above, NHANES 1999–2010. The prevalence of diabetes (including diagnosed and
undiagnosed diabetes) was calculated among all participants; the prevalence of prediabetes was calculated among participants excluding the
diagnosed and undiagnosed diabetes.
doi:10.1371/journal.pone.0097865.g001
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Thus, FINDRISC can work as an initial screening tool at the
community or population level for American adults aged 20 or
above, for Whites, Blacks, and Hispanics. The large sample size is
also the strength of our study, which can produce more reliable
results. Combined with the multiple racial/ethnic feature of our
study population, this allows us to evaluate the validity of
FINDRISC in different gender and racial/ethnic strata.
Using ADA diabetes diagnosis criteria 2013 to validate
FINDRISC for the first time is another strength of our study.
Compared with WHO diabetes diagnosis criteria or only FPG
value used in previous studies of FINDRISC evaluation among
other populations, our study added HbA1c as a diagnosis criterion.
As a more convenient screening method than FPG and OGTT,
HbA1c test does not require fasting and is not influenced by the
day to day variation. HbA1c has also been found to have a very
high specificity in identifying diabetic patients in different racial/
ethnic groups [46,47]. Thus, including HbA1c as diagnosis criteria
for both diabetes and prediabetes leads to reducing the false
negative results in our study.
Another improvement in the present study is investigating the
gender and racial/ethnic difference in the performance of
FINDRISC with a single population, as well as identifying the
optimal cutoff point for each subgroup. Only in a cross-sectional
evaluation of FINDRISC in Finland, FINDRISC was evaluated
for different performance in detecting undiagnosed diabetes,
abnormal glucose tolerance and metabolic syndrome by gender.
FINDRISC was identified as performing a little better in women
than in men only in distinguishing the metabolic syndrome
without statistical significance [25]. However, in the current study
among U.S. general population, FINDRISC performs significantly
better in women than in men in detecting both undiagnosed
diabetes and prediabetes. No previous study compared the
performance of FINDRISC by race/ethnicity. In the present
study we found the FINDRISC performed significantly better in
non-Hispanic White than in Hispanics. The difference in the
performance by gender or race/ethnicity could be due to the
different sensitivity of the question by gender and race/ethnicity,
such as BMI and waist circumference. One study has found that
central obesity is more related with non-insulin-dependent
diabetes mellitus in women than in men [48], and another study
has shown that waist circumference has lower impact in metabolic
syndrome in Hispanics than in non-Hispanic White and non-
Hispanic Black [49]. The different performance in each subgroup
even supports the rationality of evaluation of FINDRISC before
applying it to a specific population. However, despite of the
different performance, our results still indicate FINDRISC is a
reliable screening tool in the general U.S. population. The
different optimal cutoff points identified in the study could be
applied to each subgroup in the practical application.
One limitation of our study is that we cannot evaluate the
FINDRISC in predicting the future incident diabetes because the
NHANES is a cross-sectional survey which did not provide follow-
up data. However, FINDRISC was developed for both predicting
future diabetes and detecting undiagnosed diabetes [16]. In
addition, detecting the prediabetes in the general population also
identifies the population at higher risk of type 2 diabetes in the
future, given the continuum of the risk for diabetes [50]. Another
limitation of current study is the possibility of misclassification on
diagnosis of diabetes and prediabetes because not all participants
have results from all 3 tests (i.e. FPG, OGTT, and HbA1C). To
Figure 2. Receiver operating characteristic (ROC) curve for identifying undiagnosed diabetes (A and B) and prediabetes (C and D)
by gender and race/ethnicity in US men and women aged 20 years or above, NHANES 1999–2010.
doi:10.1371/journal.pone.0097865.g002
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evaluate the impact of this limitation on our results, we conducted
a sensitivity analysis among individuals who had results from all 3
tests (N= 3,978). The results showed that among this subgroup of
individuals who had 3 tests results, the area under the ROC curve
was 0.71 (vs. 0.75 for all individuals) for undiagnosed diabetes and
0.67 (vs. 0.67 for all individuals) for prediabetes, indicating the
influence of the possible misclassification is minor.
Our evaluation was based on a relative healthy adult
population. Different cutoff values may be applied for other
populations such as children and adolescents and obese people.
Further research is warrantied to investigate whether the cutoffs of
FINDRISC suggested by this study could be applied to some other
specific youth and obese populations given the increased
prevalence of obesity and type 2 diabetes in children and
adolescents in the U.S..
Conclusions
In conclusion, FINDRISC can be used as a simple and non-
invasive screening tool to identify individuals at high risk for
diabetes and prediabetes in the U.S. adults. A cutoff point of 10 for
men and 12 for women are suggested to identify undiagnosed
diabetes; a cutoff point of 9 for men and 10 for women are
suggested to identify prediabetes.
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